Vimarsana
Biggest News Aggregation in the World

Page 27 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nuclear Export. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nuclear Export Today - Breaking & Trending Today

Brokerages Expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to Announce -$0.63 Earnings Per Share - Vimarsana News

Brokerages Expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to Announce -$0.63 Earnings Per Share

Published: June 1, 2022

Wall Street brokerages predict that Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Rating) will post earnings of ($0.63) per share for the current quarter, Zacks Investment Research reports. Six analysts have provided estimates for Karyopharm Therapeutics’ earnings, with estimates ranging from ($0.81) to ($0.50). Karyopharm Therapeutics reported earnings of ($0.71) per share during the same quarter […]

Source: etfdailynews.com
Related Topics:
Hong KongZurcher Kantonalbank Zurich CantonalbankSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncRunning Point Capital AdvisorsZacks Investment ResearchKaryopharm Therapeutics Company Profile Get RatingMarshall WaceJpmorgan Chase CoFirst Mercantile Trust CoRoyal BankHong Kong LtdWall StreetKaryopharm TherapeuticsGet RatingKaryopharm TherapeuticKong LtdPoint Capital AdvisorsMercantile TrustKantonalbank Zurich CantonalbankTherapeutics Company ProfileTherapeutics IncSelective InhibitorNuclear ExportNasdaq Kpti
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published: June 1, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...

Source: prnewswire.com
Related Topics:
United KingdomSelective Inhibitor Of Nuclear ExportPrnewswire Karyopharm Therapeutics IncKaryopharm Therapeutics IncGrant DateStock Incentive PlanNasdaq Listing RuleSelective InhibitorNuclear ExportKaryopharm TherapeuticsKaryopharm Therapeutics Inc
Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting - Vimarsana News

Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting

Published: May 26, 2022

– Encouraging Initial Data Observed in Phase 1/2 Study of Selinexor in Combination with Ruxolitinib in Treatment-Naïve Myelofibrosis, Including Favorable...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomKyongsang BuktoSouth KoreaAbdulazeez SalawuHaris AliReshma RangwalaOmar AlhalabiBlessie Elizabeth NelsonYasaman DamestaniVicky MakkerSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncUniversity Health NetworkUniversity Of Texas Md Anderson Cancer CenterDrug AdministrationPrnewswire Karyopharm Therapeutics IncAmerican Society Of Clinical Oncology Annual MeetingExchange CommissionEuropean Network For Gynaecological Oncological TrialKaryopharm Selective Inhibitor Of Nuclear ExportFoundation IncInformation DepartmentMemorial Sloan Kettering Cancer CenterEncouraging Initial Data Observed
The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study - Vimarsana News

The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study

Published: May 25, 2022

/PRNewswire/ -- The European Myeloma Network (EMN), an international collaborative network of expertise centers for multiple myeloma in Europe and Australia,...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomKyongsang BuktoSouth KoreaKatja WeiselMario BoccadoroReshma RangwalaPieter SonneveldSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncNational Cancer InstituteDrug AdministrationExchange CommissionKaryopharm Selective Inhibitor Of Nuclear ExportInformation DepartmentUniversity Cancer CenterAmerican Cancer SocietyEuropean Myeloma NetworkAll Oral RegimenLow Dose DexamethasoneRefractory Multiple MyelomaKaryopharm TherapeuticsChief Medical OfficerMultiple MyelomaProfessor Katja Weisel
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma - Vimarsana News

Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

Published: May 20, 2022

/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomNorthern IrelandRichard PaulsonElcin Barker ErgunSelective Inhibitor Of Nuclear ExportKaryopharm Therapeutics IncMenarini GroupDrug AdministrationEuropean CommissionWorld Health OrganizationPrnewswire Karyopharm Therapeutics IncExchange CommissionEuropean UnionEuropean Medicines AgencyEuropean Commission DecisionCommittee For Medicinal Products Human UseEuropean Commission Decision AnticipatedMedicinal ProductsHuman UseChief Executive OfficerPivotal PhaseIndependent Review CommitteeVery Good Partial ResponseMultiple Myeloma